Oakwood Laboratories L.L.C. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 23

More Info
									          Oakwood Laboratories L.L.C. – Product Pipeline
                      Review – H2 2011
                                                                                          Reference Code: GMDHC01465CDB

                                                                                                 Publication Date: OCT 2011




Oakwood Laboratories L.L.C. – Product Pipeline Review – H2 2011                             GMDHC01465CDB / Published OCT 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Oakwood Laboratories L.L.C. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 3
Oakwood Laboratories L.L.C. Snapshot ................................................................................................................................................................... 4
      Oakwood Laboratories L.L.C. Overview ............................................................................................................................................................. 4
      Key Information .................................................................................................................................................................................................. 4
      Key Facts ........................................................................................................................................................................................................... 4
Oakwood Laboratories L.L.C. – Research and Development Overview .................................................................................................................... 5
      Key Therapeutic Areas ....................................................................................................................................................................................... 5
Oakwood Laboratories L.L.C. – Pipeline Review ...................................................................................................................................................... 7
      Pipeline Products by Stage of Development ....................................................................................................................................................... 7
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 8
Oakwood Laboratories L.L.C. – Pipeline Products Glance ........................................................................................................................................ 9
      Oakwood Laboratories L.L.C. – Late Stage Pipeline .......................................................................................................................................... 9
            Registration Filed Products/Combination Treatment Modalities.................................................................................................................... 9
      Oakwood Laboratories L.L.C.–Early Stage Pipeline Products ...........................................................................................................................10
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................10
Oakwood Laboratories L.L.C. – Drug Profiles ..........................................................................................................................................................11
      Leuprolide .........................................................................................................................................................................................................11
            Product Description ....................................................................................................................................................................................11
            Mechanism of Action...................................................................................................................................................................................11
            R&D Progress .............................................................................................................................................................................................11
      Leuprolide 30 mg ..............................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      Leuprolide 45 mg ..............................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Octreotide .........................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
Oakwood Laboratories L.L.C. – Pipeline Analysis....................................................................................................................................................15
      Oakwood Laboratories L.L.C. – Pipeline Products by Therapeutic Class...................
								
To top